A new study published in the journal Nano Letters showed that cellular nanosponges may be able to inhibit SARS-CoV-2 infectivity within the body, ultimately neutralizing the virus.
Biotech and pharmaceutical companies and health care institutions are on the front lines of not only fighting COVID-19, but working to develop vaccines and therapies against the respiratory illness – often in unexpected ways.
A hot, humid summer will slow coronavirus transmission but, on its own, is not likely to end the COVID-19 pandemic, according to a new study by researchers at the Massachusetts Institute of Technology, Harvard University, the University of Connecticut and Virginia Tech.
A COVID-19 vaccine candidate under development by China’s CanSino Biologics is moving forward in development after the company published data supporting patient safety.
In a BioSpace interview, Sorrento Therapeutics executives emphasized the stringent process the company went through in identifying the antibody STI-1499, which demonstrated 100 percent inhibition of SARS-CoV-2 in laboratory tests.
Weeks after Mammoth Biosciences announced the company’s CRISPR-based diagnostics test for COVID-19 had a high degree of specificity even for asymptomatic patients, the Bay Area-based firm struck a deal with GlaxoSmithKline to accelerate development of the test in hopes of getting them in consumer hands as soon as possible.
The Centers for Disease Control and Prevention (CDC) is on the cusp of launching a massive, 25-city SARS-CoV-2 antibody study.
Prellis Biologics Inc. generated 300 human IgG antibodies that bind to either the S1 or S2 spike protein of the SARS-CoV2-Wuhan strain of the novel coronavirus.
BioSpace reviews some of the more interesting scientific studies recently published, including a Phase II clinical trial out of Hong Kong that found a three drug-antiviral cocktail significantly decreased median time to a negative SARS-CoV-2 test compared to controls.
iSpecimen will supply the U.S. Centers for Disease Control and Prevention (CDC) with serum samples from subjects who have previously tested positive for SARS-CoV-2, the virus that causes COVID-19.
